



P R E S S R E L A S E

Ocumetics Announces Completion of First Tranche of Unit Private Placement

For Immediate Release

Calgary, Alberta – July 17, 2025. Ocumetics Technology Corp. ("**Ocumetics**" or the "**Corporation**") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement previously announced by the Corporation on June 4, 2025 (the "**Offering**").

The Corporation has issued an aggregate of 3,212,462 units ("**Units**") at a price of \$0.35 per unit for aggregate gross proceeds of \$1,124,362. Each Unit consists of one common share in the share capital of the Corporation ("**Common Share**") and one-half of one common share purchase warrant. Each whole warrant ("**Warrant**") entitles the holder to purchase one additional Common Share at an exercise price of \$0.50 for a period of 24 months from the date of issuance of the Warrant.

In connection with their services as agent under the first tranche of the Offering, the Corporation paid \$68,610 to Numus Capital Corp. ("**Numus Capital**") and issued to Numus Capital warrants ("**Agent's Warrants**") entitling Numus Capital to purchase up to an aggregate of 196,029 Common Shares at a price of \$0.50 per share for a period of 24 months.

The Warrants and Agent's Warrants are subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least \$0.60 per Common Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be accelerated by the Corporation to a date that is not less than 30 days after the date that notice of such acceleration is provided to the Warrant holders by way of a press release.

The total offering is for of up to 6,000,000 Units at a price of \$0.35 per Unit for gross proceeds of up to \$2,100,000. The Corporation intends to close the rest of the offering in one or more subsequent tranches.

100% of the net proceeds are expected to be used for ongoing research and development, although the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

All securities issued under the Private Placement are subject to a hold period of four months and one day.

Closing of the Private Placement was subject to the conditional approval from the TSX Venture Exchange, which was obtained.

Related Party Transaction

Michael Edwards, a director of the Corporation, participated in the Private Placement. The Private Placement was therefore a “Related Party Transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“**MI 61-101**”). The Corporation relied upon the exemptions from the minority shareholder approval and valuation requirements set out in Sections 5.7(1)(a) and 5.5(a), respectively, of MI 61-101. The Private Placement, including the subscriptions of Mr. Edwards, was approved unanimously by the directors of the Corporation by resolution.

A material change report regarding the Private Placement was not filed 21 days before the completion of the Private Placement as 21 days prior to the completion of the Private Placement, completion of the Private Placement was uncertain and therefore did not at that time constitute a material change.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCTF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns
President and CEO
(817) 874-7564

Roger Jewett
Chief Financial Officer
roger.jewett@ocumetics.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the Company’s planned clinical trial program and other research and development activities and that they will be conducted as expected. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The

Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.